Molecular Targeted Therapies in Head and Neck Cancer

摘要: Molecular targeted therapies for head and neck cancer offer promising opportunities to improve upon clinical outcomes of conventional treatments. The toxicity profiles these agents are unique, reflecting their distinct mechanisms action, generally do not appear directly overlap or amplify the toxicities treatment modalities. Herein, we discuss strategies targeting epidermal growth factor receptor (EGFR) angiogenesis (VEGF) as models development evaluation molecular agents. We explore phase III data demonstrating measurable survival benefits with use cetuximab in locally advanced recurrent/metastatic settings. In addition, review EGFR tyrosine kinase inhibitors inhibitors, both which have shown activity cancer. Finally, new future directions incorporation